Chugai Pharmaceutical Balance Sheet Health
Financial Health criteria checks 6/6
Chugai Pharmaceutical has a total shareholder equity of ¥1,801.4B and total debt of ¥0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ¥2,069.7B and ¥268.4B respectively. Chugai Pharmaceutical's EBIT is ¥540.2B making its interest coverage ratio 67522.3. It has cash and short-term investments of ¥845.3B.
Key information
0%
Debt to equity ratio
JP¥0
Debt
Interest coverage ratio | 67522.3x |
Cash | JP¥845.32b |
Equity | JP¥1.80t |
Total liabilities | JP¥268.37b |
Total assets | JP¥2.07t |
Recent financial health updates
No updates
Recent updates
Calculating The Fair Value Of Chugai Pharmaceutical Co., Ltd. (TSE:4519)
Dec 05Chugai Pharmaceutical's (TSE:4519) Dividend Will Be ¥41.00
Oct 30Chugai Pharmaceutical Co., Ltd. Just Beat Revenue By 12%: Here's What Analysts Think Will Happen Next
Oct 29Chugai Pharmaceutical's (TSE:4519) Dividend Will Be ¥41.00
Oct 15Should You Be Adding Chugai Pharmaceutical (TSE:4519) To Your Watchlist Today?
Oct 12Chugai Pharmaceutical's (TSE:4519) Dividend Will Be ¥41.00
Sep 24Results: Chugai Pharmaceutical Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates
Jul 30Chugai Pharmaceutical (TSE:4519) Is Due To Pay A Dividend Of ¥41.00
Jul 27Estimating The Intrinsic Value Of Chugai Pharmaceutical Co., Ltd. (TSE:4519)
Jul 15Chugai Pharmaceutical (TSE:4519) Is Increasing Its Dividend To ¥41.00
Jun 19Chugai Pharmaceutical Co., Ltd.'s (TSE:4519) Business Is Trailing The Market But Its Shares Aren't
Jun 17Chugai Pharmaceutical (TSE:4519) Is Paying Out A Larger Dividend Than Last Year
May 04We Think That There Are Some Issues For Chugai Pharmaceutical (TSE:4519) Beyond Its Promising Earnings
May 01Chugai Pharmaceutical Co., Ltd. (TSE:4519) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Apr 26Chugai Pharmaceutical Co., Ltd. (TSE:4519) Investors Are Less Pessimistic Than Expected
Mar 01Financial Position Analysis
Short Term Liabilities: 4519's short term assets (¥1,481.1B) exceed its short term liabilities (¥251.4B).
Long Term Liabilities: 4519's short term assets (¥1,481.1B) exceed its long term liabilities (¥16.9B).
Debt to Equity History and Analysis
Debt Level: 4519 is debt free.
Reducing Debt: 4519 had no debt 5 years ago.
Debt Coverage: 4519 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 4519 has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/21 05:34 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Chugai Pharmaceutical Co., Ltd. is covered by 29 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Atsushi Seki | Barclays |
Koichi Mamegano | BofA Global Research |
Siti Bte Salikin | CFRA Equity Research |